WallStreetZenWallStreetZen

NYSE: OGN
Organon & Co Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

OGN past earnings growth

How has OGN's earnings growth performed historically?
Company
-32.11%
Industry
-7.33%
Market
35.95%
OGN's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
OGN's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance

OGN past revenue growth

How has OGN's revenue growth performed historically?
Company
-2.94%
Industry
-0.2%
Market
13.63%
OGN's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
OGN's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance

OGN earnings and revenue history

Current Revenue
$6.2B
Current Earnings
$754.0M
Current Profit Margin
12.2%

OGN Return on Equity

Current Company
-92.8%
Current Industry
37.1%
Current Market
-0.3%
OGN's Return on Equity (-92.8%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when OGN announces earnings.

OGN Return on Assets

Current Company
7%
Current Industry
8.5%
OGN is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

OGN Return on Capital Employed

Current Company
15.98%
Current Industry
14.1%

OGN vs General Drug Manufacturer Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
OGN$6.17B$1.60B$754.00M-1.26%-34.36%
GRFS$6.59B$1.31B$226.39M+4.47%-22.28%
AMRN$346.27M-$44.75M-$38.30M+11.85%N/A
SCLX$46.46M-$46.30M-$53.79M+77.59%N/A
HZNP$3.64B$901.54M$438.00M+27.71%+34.31%
View Top General Drug Manufacturer Stocks

OGN earnings dates

Next earnings date
Nov 1, 2023

Organon & Co Earnings & Revenue FAQ

What were OGN's earnings last quarter?

On Invalid Date, Organon & Co (NYSE: OGN) reported Q2 2023 earnings per share (EPS) of $0.95, up 3.26% year over year. Total Organon & Co earnings for the quarter were $242.00 million. In the same quarter last year, Organon & Co's earnings per share (EPS) was $0.92.

If you're new to stock investing, here's how to buy Organon & Co stock.

What was OGN's earnings growth in the past year?

As of Q4 2023, Organon & Co's earnings has grown -32.11% year over year. This is 24.78 percentage points lower than the US Drug Manufacturers - General industry earnings growth rate of -7.33%. Organon & Co's earnings in the past year totalled $754.00 million.

What is OGN's earnings date?

Organon & Co's earnings date is Invalid Date. Add OGN to your watchlist to be reminded of OGN's next earnings announcement.

What was OGN's revenue last quarter?

On Invalid Date, Organon & Co (NYSE: OGN) reported Q2 2023 revenue of $1.61 billion up 1.45% year over year. In the same quarter last year, Organon & Co's revenue was $1.59 billion.

What was OGN's revenue growth in the past year?

As of Q4 2023, Organon & Co's revenue has grown -2.94% year over year. This is 2.74 percentage points lower than the US Drug Manufacturers - General industry revenue growth rate of -0.2%. Organon & Co's revenue in the past year totalled $6.17 billion.
©2023 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.